
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
[ Tue, Jan 03rd 2023 ]: WOPRAI
Raghuram Selvaraju Maintained (AVXL) at Strong Buy with Increased Target to $50 on, Jan 3rd, 2023


🞛 This publication is a summary or evaluation of another publication
Raghuram Selvaraju of HC Wainwright & Co., Maintained "Anavex Life Sciences Corp." (AVXL) at Strong Buy with Increased Target from $42 to $50 on, Jan 3rd, 2023.
Raghuram has made no other calls on AVXL in the last 4 months.
There is 1 other peer that has a rating on AVXL. Out of the 1 peers that are also analyzing AVXL, all agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Charles Duncan of "Cantor Fitzgerald" Downgraded from Buy to Hold and Decreased Target to $11 on, Tuesday, December 6th, 2022